fda label semaglutide naion warning 2025 The obesity drug (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of data showed. Added Update on the link between

If unwanted weight gain occurs off treatment, they can restart Semaglutide injections at any time.

Their analysis indicated that GLP-1 agonists were associated with reduced risks of cognitive decline, seizures, repeat hemorrhages and death

aggressive mixing can damage molecular structure and reduce potency

The recommended starting dosage of the injectable version of semaglutide for diabetes is 0.25 mg injected subcutaneously once a week for 4 weeks, followed by 0.5 mg once a week for 4 weeks

When to choose obesity medicine: If weight loss is your primary goal, you want comprehensive support beyond just medication, youve struggled with weight long-term, or you want a provider who specializes in this area